Abstract

Emerging bovine somatotropin (or “bovine growth hormone” [bGH]) technology has become highly controversial even though the technology is one to two years from commercial introduction. The bGH controversy is discussed and placed in the context of the evolution of the American public agricultural research system and farm structural change over the past 15 years. It is argued that while many observers tend to overestimate the degree to which bGH will be representative of other biotechnologies applied to agriculture, the bGH case may well reflect a more general pattern of the changing clientele relations of the land-grant system and of the changing character of technology developed within the public agricultural research system. In particular, these new clientele and technical relations may portend a new era in which farmers begin to scrutinize the land-grant research portfolio, which might in turn lead to diminished political support by state-level farmers' groups for agricultural research appropriations